# Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer

> **NCT00054418** · PHASE3 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 216 (actual)

## Conditions studied

- Breast Cancer
- Osteoporosis

## Interventions

- **DIETARY_SUPPLEMENT:** calcium carbonate
- **DIETARY_SUPPLEMENT:** vitamin D
- **DRUG:** risedronate sodium
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00054418
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2007-04
- **Final completion:** 2008-05
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2016-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00054418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00054418, "Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00054418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*